Instil Bio Files 8-K with Regulatory Updates
Ticker: TIL · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1789769
| Field | Detail |
|---|---|
| Company | Instil Bio, INC. (TIL) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, financials
TL;DR
Instil Bio filed an 8-K on 9/16/24 covering regulatory disclosures and other events.
AI Summary
Instil Bio, Inc. filed an 8-K on September 16, 2024, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company's principal executive offices are located at 3963 Maple Avenue, Suite 350, Dallas, Texas.
Why It Matters
This 8-K filing provides important updates and disclosures from Instil Bio, Inc. to the public and its investors regarding company events and financial information.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting standard corporate events and disclosures, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 001-40215 — SEC File Number (Identifies Instil Bio, Inc. in SEC filings.)
- 83-2072195 — IRS Employer Identification No. (Tax identification number for Instil Bio, Inc.)
Key Players & Entities
- Instil Bio, Inc. (company) — Registrant
- September 16, 2024 (date) — Date of Report
- 3963 Maple Avenue, Suite 350, Dallas, Texas 75219 (location) — Principal Executive Offices
- 001-40215 (company_id) — SEC File Number
FAQ
What specific events are being disclosed in this 8-K filing?
The filing indicates disclosures related to Regulation FD, Other Events, and Financial Statements and Exhibits.
When was this 8-K report filed?
The report was filed on September 16, 2024.
Where are Instil Bio, Inc.'s principal executive offices located?
The principal executive offices are located at 3963 Maple Avenue, Suite 350, Dallas, Texas 75219.
What is the SEC file number for Instil Bio, Inc.?
The SEC file number for Instil Bio, Inc. is 001-40215.
What is the fiscal year end for Instil Bio, Inc.?
The fiscal year end for Instil Bio, Inc. is December 31.
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-09-16 06:02:25
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value TIL The Nasdaq Stock Market L
Filing Documents
- til-20240916.htm (8-K) — 34KB
- instilbiocorppres2024091.htm (EX-99.1) — 12KB
- pr8-kpressrelease.htm (EX-99.2) — 15KB
- image_0.jpg (GRAPHIC) — 3KB
- instilbiocorppres2024091001.jpg (GRAPHIC) — 69KB
- instilbiocorppres2024091002.jpg (GRAPHIC) — 298KB
- instilbiocorppres2024091003.jpg (GRAPHIC) — 106KB
- instilbiocorppres2024091004.jpg (GRAPHIC) — 116KB
- instilbiocorppres2024091005.jpg (GRAPHIC) — 112KB
- instilbiocorppres2024091006.jpg (GRAPHIC) — 126KB
- instilbiocorppres2024091007.jpg (GRAPHIC) — 136KB
- instilbiocorppres2024091008.jpg (GRAPHIC) — 110KB
- instilbiocorppres2024091009.jpg (GRAPHIC) — 68KB
- instilbiocorppres2024091010.jpg (GRAPHIC) — 119KB
- instilbiocorppres2024091011.jpg (GRAPHIC) — 115KB
- instilbiocorppres2024091012.jpg (GRAPHIC) — 49KB
- 0001628280-24-040396.txt ( ) — 2161KB
- til-20240916.xsd (EX-101.SCH) — 2KB
- til-20240916_lab.xml (EX-101.LAB) — 22KB
- til-20240916_pre.xml (EX-101.PRE) — 13KB
- til-20240916_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Instil Bio, Inc. (the "Company") from time to time presents and/or distributes to the investment community presentations related to its business. A copy of its most recent presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1. The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. On September 16, 2024, the Company issued a press release entitled "Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer". A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Instil Bio Corporate Presentation dated September 2024 99.2 Press release dated September 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Instil Bio, Inc. Dated: September 16, 2024 By: /s/ Sandeep Laumas, M.D. Sandeep Laumas, M.D. Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer)